Obesity Case 12

A 47-year-old woman with primary hypothyroidism and osteoarthritis of the right knee presented to the clinic for follow-up.  She is trying to lose weight in preparation for right knee surgery.  The weight loss has plateaued on a low-calorie meal plan.  Her exercise is limited by chronic knee pain.  She tracks her calories and daily steps.  After the discussion about the risks and benefits of weight loss medications, she was started on phentermine/topiramate extended-release daily.  She returns three months later and has lost 3% of her body weight since the last visit.  On physical examination, her BMI is 34 kg/m². She has decreased range of motion of right knee. Otherwise, the physical examination is unremarkable.

Question 1

Which of the following is true for cardiometabolic risk markers after weight loss?

A. Increase in hs-CRP and decrease in adiponectin
B. Increase in both hs-CRP and adiponectin
C. Decrease in both hs-CRP and adiponectin
D. Decrease in hs-CRP and an increase in adiponectin
Incorrect!
Correct!
Correct Answer
D. Decrease in hs-CRP and an increase in adiponectin

The effect of phentermine/topiramate extended-release on cardiometabolic risk factors include lowering of hs-CRP and an increase in adiponectin.  There is a reduction in systolic and diastolic blood pressure, reduction in triglycerides, total cholesterol and LDL cholesterol, and an increase in HDL cholesterol with weight loss.

The effect of phentermine/topiramate extended-release on cardiometabolic risk factors include lowering of hs-CRP and an increase in adiponectin.  There is a reduction in systolic and diastolic blood pressure, reduction in triglycerides, total cholesterol and LDL cholesterol, and an increase in HDL cholesterol with weight loss.